Disparity In Breast Cancer Population Is Challenge For FDA: Can Genetic Testing Help?
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.
You may also be interested in...
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
NIH official has published articles urging drug development focused on metastasis-prevention.
FDA doesn’t seem ready to support clinical trial endpoint asked for by metastatic breast cancer patients at patient-focused drug development meeting.